The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background & Aims Hepatocellular carcinoma (HCC) typically arises in fibrotic or cirrhotic livers, which are characterized by pathogenic angiogenesis. Myeloid immune cells, specifically tumor-associated macrophages (TAMs), may represent potential novel therapeutic targets in HCC, complementing current ablative or immune therapies. However, the detailed functions of TAM subsets in hepatocarcinogenesis have remained obscure. Methods TAM subsets were analyzed in-depth in human HCC samples and a combined fibrosis–HCC mouse model, established by i.p. injection with diethylnitrosamine after birth and repetitive carbon tetrachloride (CCl 4 ) treatment for 16 weeks. Based on comprehensively phenotyping TAM subsets (fluorescence-activated cell sorter, transcriptomics) in mice, the function of CCR2 + TAM was assessed by a pharmacologic chemokine inhibitor. Angiogenesis was evaluated by contrast-enhanced micro–computed tomography and histology. Results We show that human CCR2 + TAM accumulate at the highly vascularized HCC border and express the inflammatory marker S100A9, whereas CD163 + immune-suppressive TAM accrue in the HCC center. In the fibrosis–cancer mouse model, we identified 3 major hepatic myeloid cell populations with distinct messenger RNA profiles, of which CCR2 + TAM particularly showed activated inflammatory and angiogenic pathways. Inhibiting CCR2 + TAM infiltration using a pharmacologic chemokine CCL2 antagonist in the fibrosis–HCC model significantly reduced pathogenic vascularization and hepatic blood volume, alongside attenuated tumor volume. Conclusions The HCC microenvironment in human patients and mice is characterized by functionally distinct macrophage populations, of which the CCR2 + inflammatory TAM subset has pro-angiogenic properties. Understanding the functional differentiation of myeloid cell subsets in chronically inflamed liver may provide novel opportunities for modulating hepatic macrophages to inhibit tumor-promoting pathogenic angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×
“It therefore is conceivable that modulating hepatic macrophages could effectively remodel the tumor microenvironment,(6,7) which may prevent HCC development or may enhance the efficacy of chemotherapy, immune checkpoint inhibition, or antiangiogenic therapies.(8,9) The tumor microenvironment contains multiple myeloid…”
BackgroundLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Self-citationPromotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076 · cited 2×
“Although myeloid cells in livers with established tumors typically are immune-suppressive and associated with a poor prognosis,(21) the characteristic sequence of long-standing chronic liver disease, fibrosis, and, ultimately, HCC development, offers the potential for chemopreventive approaches by modulating hepatic m…”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003 · cited 2×
“Although myeloid cells in livers with established tumors typically are immune-suppressive and associated with a poor prognosis,(21) the characteristic sequence of long-standing chronic liver disease, fibrosis, and, ultimately, HCC development, offers the potential for chemopreventive approaches by modulating hepatic m…”
BackgroundSelf-citationEggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609 · cited 1×
“For instance, CCR2þ monocytederived macrophages can suppress early tumor formation by clearing senescent hepatocytes, although they may promote hepatocarcinogenesis in established tumors.(18) Similarly, inhibiting CCR2þ macrophage recruitment reduced the tumor burden in models of subcutaneous implantation of hepatoma…”
BackgroundGeorgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Fibrosis-dependent mechanisms of hepatocarcinogenesis
Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444 · cited 2×
“Enhanced angiogenesis with the formation of a pathogenic vasculature is a common feature of liver fibrosis(3) and is considered a key component of a tumor-promoting or tumor-sustaining stroma.(4) We previously showed that pathogenic angiogenesis in hepatic fibrosis is driven by liver-infiltrating, monocyte-derived mac…”
BackgroundMossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325 · cited 1×
“The CCR2þ cells at the tumor border showed a round monocyte-like morphology, and a substantial fraction of them expressed S100A9, indicating an inflammatory polarization.(22) Fewer CCR2 or S100A9 expressing TAMs were found at the tumor”
BackgroundSelf-citationAngiogenesis in chronic liver disease and its complications: Angiogenesis in CLD
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02369.x · Cited by 276
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis
Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Möckel, D., Baeck, C., Hittatiya, K., Eulberg, D., Luedde, T., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306294 · Cited by 273 · cited 6×
“We previously showed that pathogenic angiogenesis in hepatic fibrosis is driven by liver-infiltrating, monocyte-derived macrophages that are being recruited to chronically injured livers via the C-C motif chemokine receptor 2 (CCR2).(5) It therefore is conceivable that modulating hepatic macrophages could effectively…”
BackgroundMethodResultInfluentialSelf-citationHistidine‐rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease
Bartneck, M., Fech, V., Ehling, J., Govaere, O., Warzecha, K. T., Hittatiya, K., Vucur, M., Gautheron, J., Luedde, T., Trautwein, C., et al. (2016) · Hepatology · doi:10.1002/hep.28418 · Cited by 101
Self-citation
Cited by
Korbecki, J., Kojder, K., Simińska, D., Bohatyrewicz, R., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218412 · Cited by 465
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Cheng, K., Cai, N., Zhu, J., Yang, X., Liang, H., & Zhang, W. (2022) · Cancer Communications · doi:10.1002/cac2.12345 · Cited by 460
Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Xu, M., Wang, Y., Xia, R., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13115 · Cited by 382
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Self-citationNon-cell-autonomous cancer progression from chromosomal instability
Li, J., Hubisz, M. J., Earlie, E. M., Duran, M. A., Hong, C., Varela, A. A., Lettera, E., Deyell, M., Tavora, B., Havel, J. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06464-z · Cited by 307
Metadata
- Authors
- Bartneck, M., Schrammen, P. L., Möckel, D., Govaere, O., Liepelt, A., Krenkel, O., Ergen, C., McCain, M. V., Eulberg, D., Luedde, T., Trautwein, C., Kiessling, F., Reeves, H., Lammers, T., & Tacke, F.
- Venue
- Cellular and Molecular Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 7
- Issue
- 2
- Pages
- 371-390
- ISSN
- 2352-345X (ISSN-L)
- OpenAlex
- W2897645267
- Cited by
- 107
- References
- 14
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.